Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

FoundationOne® Liquid CDx

FDA Approved
Related tests:
FoundationOne® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements and copy number losses only in BRCA1 and BRCA2. FoundationOne® Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne® Liquid CDx cfDNA blood collection tubes included in the FoundationOne® Liquid CDx Blood Sample Collection Kit. FoundationOne Liquid CDx is Intended to be used as a companion diagnostic for: EGFR Exon 19 deletions and EGFR Exon 21 L858R substitution in NSCLC with therapy TRESSA® (gefitinib), TAGRISSO® (osimertinib), TARCEVA® (erlotinib) and for BRCA1, BRCA2 alterations in mCRPC with therapy RUBRACA® (rucaparib).
Breast Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), ATM (ATM serine/threonine kinase), BRAF (B-raf proto-oncogene)
See More ...
Alecensa (alectinib), Alunbrig (brigatinib), Braftovi (encorafenib), Erbitux (cetuximab), Exkivity (mobocertinib), Lynparza (olaparib), Mektovi (binimetinib), Piqray (alpelisib), Rozlytrek (entrectinib), Rubraca (rucaparib), Tabrecta (capmatinib), Tagrisso (osimertinib), erlotinib, gefitinib
Next-Generation Sequencing (NGS)
Confirmatory trial(s)